Proposal to list Interventional Radiology products supplied by Endologix and Device Technologies
What we’re proposing
PHARMAC is seeking feedback on a proposal to list a range of Interventional Radiology Products in Part III of Section H of the Pharmaceutical Schedule from 1 August 2018 through provisional agreements with Endologix New Zealand Co (“Endologix”) and Device Technologies NZ Limited (“Device Technologies”).
Consultation closes at 5pm on 21 June 2018 and feedback can be emailed to email@example.com.
What would the effect be?
These proposed agreements would supersede any existing DHB contracts with these suppliers for the devices proposed for listing 1 August 2018, subject to consultation and approval by PHARMAC’s Board or delegate (“Agreements”).
The agreements would provide consistent terms and conditions for these devices for all DHB purchases from the proposed date of listing on the Pharmaceutical Schedule.
PHARMAC estimates that the Endologix agreement would offer national savings to DHBs of $15,000 per annum, based on current usage.
PHARMAC estimates that the agreement with Device Technologies would be cost neutral to DHBs, based on current usage.
DHBs would be able to continue to procure other suppliers’ ranges of Interventional Radiology Products, as the Agreements would not be for sole supply.
DHBs would have access to educational services which would be tailored to suit the needs of the individual DHB Hospitals.
Who we think will be interested
- Suppliers and Wholesalers
- DHB Staff
- Interventional Radiology staff
- Procurement and supply chain personnel
About Interventional Radiology products
Interventional radiology refers to a range of minimally invasive alternatives to surgery to diagnose and treat a variety of conditions, that are performed using radiologic imaging guidance to precisely target the intervention. The procedures are performed using catheters inserted via either radial or femoral arteries or veins.
The imaging modalities used include general radiography including fluoroscopy, angiography, ultrasound, computed tomography, and magnetic resonance imaging.
Interventional radiology in some form is performed in all hospitals across New Zealand.
Why we’re proposing this listing
In September 2017 PHARMAC issued a Request for Proposals for interventional radiology products. The RFP was for non-exclusive national agreements for listing on the Pharmaceutical Schedule.
PHARMAC has been working with suppliers in order to seek provisional agreements and this is the first proposal to arise from that process. We intend to consult on proposed agreements with other suppliers over the next few months.
Details about our proposal
PHARMAC has entered into a provisional agreement with Endologix for a range of Interventional Radiology Products that would result in listing 123 products on the Pharmaceutical Schedule from 1 August 2018.
PHARMAC has also entered into a provisional agreement with Device Technologies for a range of interventional radiology products that would result in listing 22 products on the Pharmaceutical Schedule from 1 August 2018.
A full list of the products has not been included in this consultation for brevity, however we are making it available along with pricing information to appropriate DHB personnel.
DHBs would be able to continue to choose which Interventional Products they procure.
The following information provides a summary of the brands and product ranges in the proposed agreements:
To provide feedback
Send us an email: firstname.lastname@example.org by 5:00pm on 21 June 2018.
All feedback received before the closing date will be considered by PHARMAC’s Board (or its delegate) prior to making a decision on this proposal.
Feedback we receive is subject to the Official Information Act 1982 (OIA) and we will consider any request to have information withheld in accordance with our obligations under the OIA. Anyone providing feedback, whether on their own account or on behalf of an organisation, and whether in a personal or professional capacity, should be aware that the content of their feedback and their identity may need to be disclosed in response to an OIA request.
We are not able to treat any part of your feedback as confidential unless you specifically request that we do, and then only to the extent permissible under the OIA and other relevant laws and requirements. If you would like us to withhold any commercially sensitive, confidential proprietary, or personal information included in your submission, please clearly state this in your submission and identify the relevant sections of your submission that you would like it withheld. PHARMAC will give due consideration to any such request.